Manager TitleAgeSince
President - 14/12/2023
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 57 14/12/2023
Director/Board Member - 14/12/2023
Date Insider Type Main position Quantity % Market Cap. Importance
12/14/23 A Issuer sale

Director

127,934 0.0678%
12/14/23 A Issuer sale

Chief Executive Officer

643,595 0.3411%
12/14/23 A Issuer sale

Director

97,934 0.0519%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%+4.77% - - 43.15B
-2.54%-2.84%-1.90%+14.52% 48.93B
-0.40%+1.03%+439.20%+499.20% 45.01B
-1.42%+2.30%+45.46%+19.36% 44.07B
-1.22%-2.31%+12.40%+71.48% 40.73B
+0.53%-1.36%+16.04%+48.23% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+22.59%+116.19% 16.5B
-1.01%+0.50%+15.83%+27.98% 14.67B
-1.65%-1.03%+77.75%+37.63% 13.77B
Average -0.83%+0.53%+78.42%+104.33% 30.55B
Weighted average by Cap. -0.90%+0.11%+94.86%+122.11%
Logo Seagen Inc.
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).
Employees
3,256
  1. Stock Market
  2. Stocks
  3. SGEN Stock